DOCSLIB.ORG

Hepatitis C Virus

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hepatitis C Virus Hepatitis C Virus A New Era Begins HCV • Prevalence • Clinical Issues • HCV Life Cycle • Emerging DAAs Global HCV Prevalence HCV Regional Prevalence Region Anti-HCV (%) No. HCV-infected Asia 3.8% 116,000,000 China, Pakistan, Japan, Thailand N.Africa/Middle East 3.6 15,00,000 Africa 2.5 18,000,000 Europe 2.4 20,000,000 North America 1.3 4,000,000 World Pop (2005) 2.8 >184,000,000 6.5 billion Hanafiah KM et al Hep 2013 ;57: 1333 Diagnostic Barriers USA Only 50% had screening HCV-Ab 50% + HCV-Ab had HCV-RNA testing 7-11% had a liver bx or treated Overall SVR estimated 5-6% Holmberg SD et al NEJM 2013 368;1859 Screening IOM – 75% of Americans unaware Missed diagnosis M- ALT 30 IU/ml, F- 19 IU/ml Ann Int Med 2002;137:1-37 Risked-based vs birth-cohort screening – >800,000 additional cases identified – Cost-saving $35,700/life-saved with DAA+PR Ann Int Med 2012;156:263 Birth-cohort screening – USP-STF – designation “B” • ACA – covers grades A, B Clinical Spectrum ACUTE HCV ASYMPTOMATIC CHRONIC RESOLVES DIAGNOSIS 80-85% 15-20% MILD/MOD CIRRHOSIS DEATH/HCC CHC 80% 20% 1-4%/yr 0 5 10 20 30 YEARS Clinical Decisions – Who To Treat Pathology Outlines.com 2012 The HCV Life Cycle HCV Cell Cultures 1) Replicons- engineered HCV genomes NS3-5B sufficient for replication only intracellular steps Lohmann V et al Science 1999; 285:110 2) HCVpp- HCV E1 and E2 surrounded by a lipid membrane, host cell binding, entry and uncoating J Exp Med 2003; 197:633 3) HCVcc- replication in-vitro and in-vivo provides key insights into the assembly and release Kato T et al Gastroenterology 2003;125:1808 Lindenbach BD et al Science 2005, 309:623 NS3/4A protease inhibitors Drug name Lead Companies Study Phase Simeprevir Medivir/Janssen approved ABT-450/r AbbVie NDA Asunaprevir Bristol-Myers Squibb NDA Faldaprevir Boehringer Ingelheim NDA Danoprevir/r Roche Vedroprevir Gilead Sovaprevir Achillion MK-5172 Merck & Co. Nature Review/Drug Discovery June/2013 NS5B polymerase inhibitors Drug name Companies Study Phase Nucleoside/nucleotide Sofosbuvir Gilead approved uridine nucleotide Mericitabine Roche Cytidine nucleoside VX-135 Vertex uridine nucleotide Non-nucleoside Dasabuvir AbbVie NDA BI-207127 Boehringer Ingelheim Tegobuvir Gilead ABT-072 AbbVie BMS-791325 Bristol-Myers Squibb TMC-647055 Janssen NS5A inhibitors Drug Name Lead companies Phase Obitasvir AbbVie NDA Daclatasvir Bristol-Myers Squibb NDA Ledipasvir Gilead NDA ACH-3102 Achillion GSK2336805 GlaxoSmithKline MK-8742 Merck & Co PPI-668 Presidio NEUTRINO STUDY Sofosbuvir + Peg + Riba 12wks, n=327 naïve, GT 1, 4, 5, 6 100 99 80 99 90 60 91 40 20 Viral clearance clearance Viral 0 wk 2 wk 4 wk 12 SVR12 SVR12 80% cirrhosis n=54 ; SVR12 87% AA n=54 Lawitz E et al NEJM 2013;368:1878 FISSION STUDY Sofosbuvir + Riba 12 wks, naïve, GT 2,3 12 SVR n=103 n=24 n=284 n=75 Jacobson IM et al NEJM 2013;368:1867 FUSION STUDY Sofosbuvir + Riba Non-responders, GT2,3 Jacobson IM et al NEJM 2013;368:1867 100 96 100 80 78 12 60 63 61 60 SOF+R 12wks 40 SOF+R 16wks SVR 37 20 19 26 23 10 9 38 40 26 23 0 no cirrhosis cirrhosis no cirrhosis cirrhosis Genotype 2 Genotype 3 COSMOS STUDY 12wks,GT-1, Nonresponders, F0-2 Simeprevir + Sofosbuvir + Simeprevir + Sofosbuvir Riba N=40 N=40 SVR 96% SVR 93% Sulkowski M, et al EASL Annual Meeting April 2014 Current AASLD/IDSA Rec's • Naive GT-1 – Sofosbuvir 400mg + Peg + Riba: 12 wks • GT1a SVR 92% • GT1b SVR 82% • Cirrhosis SVR 78% • Ineligible for Interferon Therapy – Sofosbuvir + Simeprevir Current AASLD/IDSA Rec's • GT-2 (+/- cirrhosis) – Sofosbuvir 400mg + Riba for 12 wks – SVR 94% • GT-3 (without cirrhosis) – Sofosbuvir + Riba for 24 wks – SVR 93% naive, 77% tx-experienced Interferon-Free Trials For GT-1 Study NS3/4a PI NS5B – NI NS5B - NNI NS5A Ribavirin Abbvie ABT-450/r Dasabuvir Obitasvir +/- Gilead Sofosbuvir Ledipasvir yes Sofosbuvir Daclatasvir +/- Sofosbuvir yes BMS Asunaprevir BMS791325 Daclatasvir Asunaprevir Daclatasvir +/- Vertex Teleprevir VX-222 yes ION-I Ledipasvir and Sofosbuvir Naive HCV GT 1 +/- cirrhosis 12 wk 12 wk 24 wk 24 wk LDV/SOF + R LDV/SOF LDV/SOF + R LDV/SOF n=214 n=217 n=217 n=217 SVR 211 SVR 211 SVR 212 SVR 215 (99%) (97%) (98%) (99%) GT 1a > 97%, > 94% cirrhosis, > 91% AA AE: Fatigue, HA, Nausea, Insomnia 8-25%, 0 discontinuation 12wk arms Afdhal N et al: N Engl J Med 2014;370:1889-98 ION-II Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1, +/- Cirrhosis 12 wks 12 wks 24 wks 24 wks LDV/SOF LDV/SOF+R LDV/SOF LDV/SOF+R N=109 N=111 N=109 N=111 SVR 102 SVR 107 SVR 108 SVR 110 (94%) (96%) (99%) (99%) Afdhal N et al. N Engl J Med 2014; 370:1483-1493 ION-III Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis 8 wks 8 wks 12 wks LDV/SOF LDV/SOF + Riba LDV/SOF n=215 n=216 n=216 SVR 202 SVR 201 SVR 206 (94%) (93%) (95%) Kowdley K et al N Engl J Med 2014;370:1879-88 Abbvie Pharmaceutical non-interferon based clinical trials: 3DAAs +/- Ribavirin • ABT-450/r Protease inhibitor • Ombitasvir NS5a • Dasabuvir NS5b (bid) PEARL-III Naïve GT1b PEARL IV Naïve GT 1a No Cirrhosis GT 1b GT 1b GT 1a GT 1a 3 DAAs + R 3DAAs no R 3 DAAs + R 3DAAs no R 12 wks 12 wks 12 wks 12 wks N=210 N=209 N=100 N=205 SVR 209 SVR 207 SVR 97 SVR 185 (99.5%) (99%) (97%) (90.2%) F/R 1/0 F/R 0/2 F/R 1/2 F/R 6/10 Ferenci P et al. N Engl J Med 2014;370:1983-1992. SAPPHIRE-II Previously Treated GT1 GT 1a GT 1b 3DAAs + R 3 DAAs + R N=173 N=123 SVR 166 SVR 119 (96%) (96.7%) F/R 0/3 F/R 0/4 Prior Relapse, Partial Responders or Null Responders: SVR 95%, 100%, 95%, respectively Zeuzem S et al. N Engl J Med 2014;370:1604-1614. TURQUOISE-II 3 DAAs + Riba HCV with Cirrhosis- Naïve and Failed Therapy Poordad F et al. N Engl J Med 2014;370:1973-1982. Milestones of HCV Therapy 1989-98 1998-01 2001-11 2011-13 2013-14 2015 100 95 90 80 80 70 70 60 50 45 SVR 40 30 30 20 20 10 0 IFN mono IFN/RIBA PEG/Riba PEG/R/PI PEG/R/NS5b NS5b/NS5a Kabiri M, et al Ann Int Med 2014;161:170-180 Final Thoughts Diagnosis Oral Regimen Pill burden Effective Safety Cost ? Treating mild HCV .
Load more

Recommended publications
  • UNO Template
    26 November 2013 Americas/United States Equity Research Biotechnology Global Biotech & Pharma: The HCV Revolution - Edition 2 Research Analysts COMMENT Ravi Mehrotra PhD 212 325 3487 [email protected] What Is The N Number: Keeping An Eye On Vamil Divan, MD 212 538 5394 Potential Longer Term Pricing Disruption [email protected] Koon Ching PhD ■ No pricing disruption expected in the near-term, but potential exists in 212 325 6286 the medium- to long-term. OK this is somewhat obvious, but bear with us: [email protected] Value/NPV = Price x Mkt Share x Mkt Size x Mkt Longevity. This is the Bruce Nudell PhD second note in our "The HCV Revolution" series. HCV is clearly a highly 212 325 9122 competitive therapeutic area with many players vying for their share of the [email protected] potentially >$15B/year HCV market. We previously addressed immediate- European Pharma Team 44 207 888 0304 term pricing of next-generation regimens, specifically for Sofosbuvir (LINK). [email protected] In this note, we simply highlight the potential number of competing all-oral, Ronak H. Shah, Pharm.D., CFA IFN-free regimens, and timing of key data, in HCV (Exhibits 1-7). The 212 325 9799 number of ultimate competitors has important implications for the HCV [email protected] market. In our view, in a HCV market with up to 4−5 players, we expect Lee Kalowski "normal drug rules" to apply: i.e. the order to market, overall clinical profile of 212 325 9683 drug, and commercial prowess will primarily dictate market share, with price [email protected] used as a tool but not in a "disruptive" way.
    [Show full text]
  • Design and Synthesis of Hepatitis C Virus NS3 Protease Inhibitors
    Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 197 Design and Synthesis of Hepatitis C Virus NS3 Protease Inhibitors Targeting Different Genotypes and Drug-Resistant Variants ANNA KARIN BELFRAGE ACTA UNIVERSITATIS UPSALIENSIS ISSN 1651-6192 ISBN 978-91-554-9166-6 UPPSALA urn:nbn:se:uu:diva-243317 2015 Dissertation presented at Uppsala University to be publicly examined in B41 BMC, Husargatan 3, Uppsala, Friday, 27 March 2015 at 09:15 for the degree of Doctor of Philosophy (Faculty of Pharmacy). The examination will be conducted in Swedish. Faculty examiner: Ulf Ellervik (Lunds tekniska högskola). Abstract Belfrage, A. K. 2015. Design and Synthesis of Hepatitis C Virus NS3 Protease Inhibitors. Targeting Different Genotypes and Drug-Resistant Variants. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 197. 108 pp. Uppsala: Acta Universitatis Upsaliensis. ISBN 978-91-554-9166-6. Since the first approved hepatitis C virus (HCV) NS3 protease inhibitors in 2011, numerous direct acting antivirals (DAAs) have reached late stages of clinical trials. Today, several combination therapies, based on different DAAs, with or without the need of pegylated interferon-α injection, are available for chronic HCV infections. The chemical foundation of the approved and late-stage HCV NS3 protease inhibitors is markedly similar. This could partly explain the cross-resistance that have emerged under the pressure of NS3 protease inhibitors. The first-generation NS3 protease inhibitors were developed to efficiently inhibit genotype 1 of the virus and were less potent against other genotypes. The main focus in this thesis was to design and synthesize a new class of 2(1H)-pyrazinone based HCV NS3 protease inhibitors, structurally dissimilar to the inhibitors evaluated in clinical trials or approved, potentially with a unique resistance profile and with a broad genotypic coverage.
    [Show full text]
  • Bristol-Myers Setback Another Blow to Hep C Field
    August 24, 2012 Bristol-Myers setback another blow to hep C field Joanne Fagg The once-crowded field of candidates jostling to be part of the first all-oral hepatitis C antiviral cocktail got decidedly emptier today with the news that Bristol-Myers Squibb had cancelled development of its $2bn asset BMS-986094. The safety worries that had triggered a clinical hold on the drug turned out too deep to accept – a death in the original heart failure patient, plus nine other hospitalised subjects resulting from heart and kidney toxicity. Excitement around the space has already dissipated with Gilead Sciences’ seemingly uninterrupted march towards the all-oral holy grail and signs that the untreated population might be smaller than was originally believed. Failure of a closely watched candidate – and indeed one validated by a big pharma deal – will do nothing to reinvigorate the interest of investors whose interest may be turning elsewhere. Hefty price tag The news is not necessarily a setback for the nucleoside NS5B polymerase inhibitor class or for Bristol-Myers, which still has a decent pipeline in spite of some failures (see tables). However, it is another knock to sentiment for developers in the hep C space – at least, the ones that are not called Gilead (Signs are growing that the hep C ship is sailing, August 1, 2012). Hepatitis C nucleoside NS5B polymerase inhibitor pipeline Status Product Company Selected trial IDs NCT01497366 NCT01542788 Phase III GS-7977 Gilead Sciences NCT01604850 NCT01641640 NCT00869661 Phase II RG7128 Gilead Sciences/Roche NCT01057667 NCT01278134 IDX184 Idenix Pharmaceuticals Partial clinical hold Phase I RO5303253 Roche NCT01181024 NCT01371162 RO5428029 Roche NCT01345942 ALS-2200 Vertex Pharmaceuticals NCT01590407 ALS-2158 Vertex Pharmaceuticals NCT01554085 As if further confirmation were needed, California-based Gilead is now decisively in the lead to get a much- heralded all-oral hepatitis C combination to the market and address those patients thought to be awaiting a therapy free of interferon and its side effects.
    [Show full text]
  • Pessimism Infects Achillion As FDA Sustains Clinical Hold
    September 30, 2013 Pessimism infects Achillion as FDA sustains clinical hold Jonathan Gardner Another disappointment for the hepatitis C project sovaprevir may have Achillion Pharmaceuticals feeling like it is starting all over again. At a time when the Connecticut-based group could be riding the bio-runup heading into the AASLD liver meeting in November, executives disclosed that the FDA would not lift the clinical hold imposed after liver enzyme elevations were detected in a drug interaction study (Another hep C safety worry buffets Achillion’s lead, July 2, 2013). Shares crashed 55% to a four-year low of $3.28 in early trading today on the news, released after Friday’s market close. Acknowledging the setback, executives signalled that they were prepared to move on, with phase II testing of alternative treatment regimens imminent; while that may be an attempt to reassure, it adds months if not years to investors’ assumptions about when Achillion will start generating a royalty stream. Just like starting over With first approval decisions for Gilead Sciences’ expected $11bn drug sofosbuvir due by December and combinations from Bristol-Myers Squibb and AbbVie making strides forward, the all-oral market looks to be well served by 2017. This year is the likely earliest point that any of Achillion’s assets could begin generating sales; in 2017, Gilead’s sofosbuvir-centred franchise is expected to yield $8.2bn in sales, according to EvaluatePharma's consensus. However, Achillion executives sought to portray the company's hep C activities as broader than sovaprevir, a protease inhibitor, highlighting the NS5A inhibitor ACH-3102, a second protease inhibitor, ACH-2684, which will report combination tests with ‘3102 next year, and a uridine-analog nucleotide, ACH-3422, which could be in the clinic next year.
    [Show full text]
  • Meeting Report: 26Th International Conference on Antiviral Research Q
    Antiviral Research 100 (2013) 276–285 Contents lists available at ScienceDirect Antiviral Research journal homepage: www.elsevier.com/locate/antiviral Review Meeting report: 26th International Conference on Antiviral Research q R. Anthony Vere Hodge Vere Hodge Antivirals Ltd, Old Denshott, Leigh, Reigate, Surrey, UK article info abstract Article history: The 26th International Conference on Antiviral Research (ICAR) was held in San Francisco, California from Received 2 August 2013 May 11 to 15, 2013. This article summarizes the principal invited lectures at the meeting. The opening Accepted 8 August 2013 symposium on the legacy of the late Antonín Holy´ included presentations on his pioneering work with Available online 21 August 2013 nucleotide analogs, which led to the development of several antiviral drugs including tenofovir. This drug has transformed the treatment of HIV infection and has recently become the first-line therapy for chronic Keywords: hepatitis B. The Gertrude Elion Award lecturer described the anti-HIV activities of the CCR5 inhibitor Human immunodeficiency virus cenicriviroc and the reverse transcriptase inhibitor festinavirÒ, and also reviewed the evaluation of bio- Hepatitis B degradable nanoparticles with adjuvant activity. The William Prusoff Award winner reported on the cre- Hepatitis C Herpesviruses ation of NAOMI, a computer model with 21 enzymes to predict the activity of nucleoside analogs against Antiviral therapy hepatitis C virus (HCV). Other invited lecturers discussed the development of countermeasures against severe dengue and the potential of RNA virus capping and repair enzymes as drug targets. Topics in the clinical symposium included the current status of the anti-HCV compounds sovaprevir, ACH-3102, miravirsen and ALS-2200; the evaluation of single-tablet regimens for HIV infection; and the investiga- tion of cytomegalovirus resistance to CMX001.
    [Show full text]
  • HCV Eradication with Direct Acting Antivirals (Daas)?
    HCV eradication with direct acting antivirals (DAAs)? Emilie Estrabaud Service d’Hépatologie et INSERM UMR1149, AP-HP Hôpital Beaujon, Paris, France. [email protected] HCV eradication with direct acting antivirals (DAAs)? HCV replication HCV genome and DAAs targets NS3 inhibitors NS5A inhibitors NS5B inhibitors Take home messages HCV viral cycle Asselah et al. Liver Int. 2015;35 S1:56-64. Direct acting antivirals 5’NTR Structural proteins Nonstructural proteins 3’NTR Metalloprotease Envelope Serine protease Glycoproteins RNA Capsid RNA helicase Cofactors Polymerase C E1 E2 NS1 NS2 NS3 NS4A NS4B NS5A NS5B Protease Inhibitors NS5A Inhibitors Polymerase Inhibitors Telaprevir Daclatasvir Nucs Non-Nucs Boceprevir Ledipasvir Simeprevir ABT-267 Sofosbuvir ABT-333 Faldaprevir GS-5816 VX-135 Deleobuvir Asunaprevir Direct Acting Antivirals: 2015 Asselah et al. Liver Int. 2015;35 S1:56-64. Genetic barrier for HCV direct acting antivirals High Nucleos(t)ide 1 mutation= high cost to Analog Inhibitors fitness, 2-3 additional mutations to increase fitness 2 st generation Protease Inhibitors n Non Nucleos(t)ide Analog Inhibitors : NS5 A Inhibitors 1 st generation Protease Inhibitors 1 mutation= low cost to fitness Low Halfon et al. J Hepatol 2011. Vol 55(1):192-206. HCV protease inhibitors (PI) Inhibit NS3/NS4A serine protease responsible for the processing of the polyprotein 1st generation 1st generation, 2nd wave 2nd generation Resistance low low high barrier Genotype activity 1: 1 a< 1b All except 3 all Drug drug Important Less Less interaction Drugs Boceprevir Simeprevir (Janssen) MK-5172 Telaprevir Faldaprevir (BI) ACH-2684 Paritaprevir (ABT-450)/r (AbbVie) Vedroprevir (Gilead) Vaniprevir (Merck) Sovaprevir (Achillion) Asunaprevir (BMS) NS3/NS4A structure Repositioning of helicase domain Self cleavage Lipid Bilayer Inactive Insertion of the Active carboxy-terminal tail Bartenschlager et al.
    [Show full text]
  • Diapositiva 1
    Resistencias & Epidemiología Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña Rapid Evolution of HCV Regimens: Easier to take/tolerate, Short Duration, Pangenotypic, Higher SVR, Eventually Oral for all patients SVR: 70-80% ≥ 90% ≥ 90% 2013 2014 2015 Genotype 2&3 Genotype 2 Genotypes 1-6 P/R SOF+RBV 12 weeks SOF+LPV ± RBV Genotypes 1 Genotype 3 ABT-450+ABT-267+ Telaprevir + P/R SOF+RBV 24 weeks ABT- 333 +RBV Boceprevir + P/R Genotypes 1-4 DCV+ASU SOF+ P/R SOF+DCV Genotypes 1&4 SMV+ P/R HCV Resistance to DAA During DAA-based treatment: ■ Rapid selection of resistance mutation may occur, eventually leading to viral break-through. Kieffer et al. Hepatology 2007; 46:631-9 Pilot-Matias et al. 46th EASL 2011, Abs1107 ■ Several changes at different positions at the NS3 protease, NS5B polymerase, and NS5A protein have been associated with loss of susceptibility to DAAs. Sarrazin et al. Gastroenterology 2010;138:447-62 MainTable 2. Main characteristics characteristics of the genotype of theactivity genotypeand resistance of DAA activity classes. and resistance of DAA classes. Genotype activity Resistance Key resistance mutations NS3 ■ First PI generation: genotypes 1 (1b >1a) Low genetic barrier First PI generation: protease (Telaprevir & Boceprevir) High cross-resistance G1a: R155K, V36M inhibitors G1b: V36M, T54A/S, A156T ■ Second wave and second PI generation: across all but genotype 3 (D168Q) Second wave and second PI generation: (Simeprevir, faldaprevir, vaniprevir, F43S, Q80K, R155K, D168A/E/H/T/V asunaprevir, sovaprevir, MK-5172, ACH-2684) NS5 Across all genotypes High genetic barrier Sofosbuvir*: nucleos(ti)de High cross-resistance G1a: S282T+(I434M) Sofosbuvir displays less antiviral activity G1b: S282T analogues againts genotypes 3 (treatment duration 24 G2a: S282T+(T179A, M289L, I293L, inhibitors weeks of sofosbuvir+RBV).
    [Show full text]
  • Twelve-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir And
    bs_bs_banner doi:10.1111/jgh.14096 HEPATOLOGY Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study Jia-Horng Kao,* Min-Lung Yu,† Chi-Yi Chen,‡ Cheng-Yuan Peng,§ Ming-Yao Chen,¶ Huoling Tang,** Qiaoqiao Chen** and Jinzi J Wu** *Graduate Institute of Clinical Medicine and Hepatitis Research Center, National Taiwan University College of Medicine and Hospital, ¶Division of Gastroenterology, Department of Internal Medicine, Taipei Medical University Shuang Ho Hospital, Taipei, †Division of Hepatobiliary, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, ‡Division of Gastroenterology, Department of Internal Medicine, Chia-Yi Christian Hospital, Chiayi, and §Division of Hepatogastroenterology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan; and **Ascletis BioScience Co., Ltd., Hangzhou, China Key words Abstract danoprevir, efficacy, hepatitis C, interferon free, ravidasvir. Background and Aim: The need for all-oral hepatitis C virus (HCV) treatments with higher response rates, improved tolerability, and lower pill burden compared with Accepted for publication 9 January 2018. interferon-inclusive regimen has led to the development of new direct-acting antiviral agents. Ravidasvir (RDV) is a second-generation, pan-genotypic NS5A inhibitor with high Correspondence barrier to resistance. The aim of this phase 2 study (EVEREST study) was to assess the ef- Jia-Horng Kao, Graduate Institute of Clinical ficacy and safety of interferon-free, 12-week RDV plus ritonavir-boosted danoprevir Medicine and Hepatitis Research Center, (DNVr) and ribavirin (RBV) regimen for treatment-naïve Asian HCV genotype 1 (GT1) National Taiwan University College of Medicine patients without cirrhosis. and Hospital, 7 Chung-Shan South Road, Taipei Methods: A total of 38 treatment-naïve, non-cirrhotic adult HCV GT1 patients were en- 10002, Taiwan.
    [Show full text]
  • Caracterización Molecular Del Perfil De Resistencias Del Virus De La
    ADVERTIMENT. Lʼaccés als continguts dʼaquesta tesi queda condicionat a lʼacceptació de les condicions dʼús establertes per la següent llicència Creative Commons: http://cat.creativecommons.org/?page_id=184 ADVERTENCIA. El acceso a los contenidos de esta tesis queda condicionado a la aceptación de las condiciones de uso establecidas por la siguiente licencia Creative Commons: http://es.creativecommons.org/blog/licencias/ WARNING. The access to the contents of this doctoral thesis it is limited to the acceptance of the use conditions set by the following Creative Commons license: https://creativecommons.org/licenses/?lang=en Programa de doctorado en Medicina Departamento de Medicina Facultad de Medicina Universidad Autónoma de Barcelona TESIS DOCTORAL Caracterización molecular del perfil de resistencias del virus de la hepatitis C después del fallo terapéutico a antivirales de acción directa mediante secuenciación masiva Tesis para optar al grado de doctor de Qian Chen Directores de la Tesis Dr. Josep Quer Sivila Dra. Celia Perales Viejo Dr. Josep Gregori i Font Laboratorio de Enfermedades Hepáticas - Hepatitis Víricas Vall d’Hebron Institut de Recerca (VHIR) Barcelona, 2018 ABREVIACIONES Abreviaciones ADN: Ácido desoxirribonucleico AK: Adenosina quinasa ALT: Alanina aminotransferasa ARN: Ácido ribonucleico ASV: Asunaprevir BOC: Boceprevir CCD: Charge Coupled Device CLDN1: Claudina-1 CHC: Carcinoma hepatocelular DAA: Antiviral de acción directa DC-SIGN: Dendritic cell-specific ICAM-3 grabbing non-integrin DCV: Daclatasvir DSV: Dasabuvir
    [Show full text]
  • Stamp-V3 1..249
    23 March 2016 Volume 23 Supplement 1 S1 Volume 23 Volume Supplement 1 P ages A1–A262 ages EUROPEAN JOURNAL OF HOSPITAL PHARMACY OF HOSPITAL JOURNAL EUROPEAN ABSTRACT BOOK 21st Congress of the EAHP 16-18 March 2016 Vienna, Austria March 2016 March Contents Volume 23 Supplement 1 | EJHP March 2016 Abstracts from the EAHP 2016 Congress A1 Clinical pharmacy A172 Other hospital pharmacy topics A104 Drug distribution A178 Pharmacokinetics and pharmacodynamics A118 Drug information and pharmacotherapy A195 Production and preparation A158 General management A214 Patient safety and risk management A167 International posters A250 Author index POSTER AWARD NOMINEES Presentations on Wednesday, 16 March, 14:00–15:30, Room 93 Time Poster number Poster nominee oral presentations Author 14:00 DD-021 Medicine supply chain of a central pharmacy: risk mapping F Charra shortage 14:10 PP-001 Contamination with cytotoxic drugs in the workplace – E Korczowska ESOP pilot study 14:20 PP-039 Double checking manipulations for complex and/or high A Alcobia Martins risk preparations 14:30 CP-055 The clinical pharmacist resolves medication related E Tudela-Lopez problems in cranio, maxillofacial and oral surgery patients 14:40 CP-085 The impact of pharmacist interventions on safety M Tovar Pozo and cost savings 14:50 CP-219 Effectiveness and safety of switching to dual antiretroviral J Luis Revuelta therapy in a treatment experienced HIV cohort 15:00 DD-027 Implementation and evaluation of an appointment based F J Alvarez Manceñido model for outpatients attended in
    [Show full text]
  • Review Resistance to Mericitabine, a Nucleoside Analogue Inhibitor of HCV RNA-Dependent RNA Polymerase
    Antiviral Therapy 2012; 17:411–423 (doi: 10.3851/IMP2088) Review Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase Jean-Michel Pawlotsky1,2*, Isabel Najera3, Ira Jacobson4 1National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France 2INSERM U955, Créteil, France 3Roche, Nutley, NJ, USA 4Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA *Corresponding author e-mail: [email protected] Mericitabine (RG7128), an orally administered prodrug passage experiments. To date, no evidence of genotypic of PSI-6130, is the most clinically advanced nucleoside resistance to mericitabine has been detected by popula- analogue inhibitor of the RNA-dependent RNA poly- tion or clonal sequence analysis in any baseline or on- merase (RdRp) of HCV. This review describes what has treatment samples collected from >600 patients enrolled been learnt so far about the resistance profile of mericit- in Phase I/II trials of mericitabine administered as mon- abine. A serine to threonine substitution at position 282 otherapy, in combination with pegylated interferon/ (S282T) of the RdRp that reduces its replication capacity ribavirin, or in combination with the protease inhibitor, to approximately 15% of wild-type is the only variant danoprevir, for 14 days in the proof-of-concept study of that has been consistently generated in serial in vitro interferon-free therapy. Introduction The approval of boceprevir and telaprevir [1,2], the first HCV variants are selected and grow when the inter- inhibitors of the non-structural (NS) 3/4A (NS3/4A) feron response is inadequate [3,4,6].
    [Show full text]
  • Global Eradication of Hepatitis C Virus: a Herculean Task Rajinder M Joshi* Nuclear Medicine and Laboratory Center, Yiaco Medical Co
    log bio y: O ro p c e i n M A l c Joshi, Clin Microbial 2014, 3:3 a c c i e n s i l s DOI: 10.4172/2327-5073.1000e118 C Clinical Microbiology: Open Access ISSN: 2327-5073 EditorialResearch Article OpenOpen Access Access Global Eradication of Hepatitis C Virus: A Herculean Task Rajinder M Joshi* Nuclear Medicine and Laboratory Center, Yiaco Medical Co. Al Adan Hospital, Kuwait Once dubbed under the entity of Non A-Non B (NANB) hepatitis with ribavirin which produced sustained virological response (SVR) in agents, Hepatitis C Virus (HCV) was finally discovered and named in about 40-50% for genotype I patients and upto 80% for other genotypes 1989 [1,2]. HCV is an enveloped single stranded positive sense 9.6 kb after 24-48 weeks therapy. Besides, the non-specific actions of RNA virus about 50 nm in diameter under the hepacivirus genus within interferon (injectable) and ribavirin (oral), these two drugs have their the Flaviviridae family. Approximately 200 million people (about 3% own undesirable side effects. With the FDA approval of two oral direct of the world population) are currently infected with HCV including acting antiviral (DAA) drugs, telaprevir and boceprevir in 2011, triple- about 4 million in USA itself. The virus has 6 major genotypes and drug regime started with the addition of one of these two oral drugs to over 50 subtypes based on the genomic heterogeneity. Some experts the earlier protocol. This not only improved SVR but also shortened recognize even more genotypes but it remains debatable until major the treatment duration.
    [Show full text]